Allergy Therapeutics (GB:AGY) has released an update.
Allergy Therapeutics, a biotech firm specializing in allergy vaccines, has appointed David Ball as an independent Non-Executive Director and Chair of the Audit and Risk Committee. Ball brings over 25 years of financial market expertise, including a tenure as equity portfolio manager with Tudor Investment Corporation, and holds degrees in engineering from Cambridge University. This strategic appointment comes at a time when the company is experiencing growth and positive developments.
For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.
